Steven George Hughes
CIK: 0001747528
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (29 total)
- Sep 18, 2026RNA
Atrium Therapeutics, Inc.
Tax Payment(F)Direct21.5K shares at avg. $8.95$192K - Apr 20, 2026RNA
Atrium Therapeutics, Inc.
Award(A)Direct30K shares- - Feb 27, 2026RNAM
Avidity Biosciences, Inc.
Disposition(D)Direct115.9K shares- - Jan 21, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct2.9K shares at avg. $72.45$209K - Jan 21, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct2K shares at avg. $72.45$146K - Jan 7, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct2.4K shares at avg. $72.23$171K - Oct 22, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct2.2K shares at avg. $10.16$22K - Oct 22, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct2.2K shares at avg. $47.54$105K - Sep 22, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct2.2K shares at avg. $40.58$90K - Sep 22, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct2.2K shares at avg. $10.16$22K - Sep 15, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct1.5K shares at avg. $45.41$70K - Sep 15, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct1.5K shares at avg. $6.57$10K - Aug 22, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct2.2K shares at avg. $10.16$22K - Aug 22, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct2.2K shares at avg. $46.40$102K - Aug 13, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct1.5K shares at avg. $46.66$72K - Aug 13, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct1.5K shares at avg. $6.57$10K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct17.7K shares at avg. $42.74$755K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct17.7K shares at avg. $10.16$179K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct6.2K shares at avg. $42.74$264K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct6.2K shares at avg. $22.47$139K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct12.3K shares at avg. $42.74$527K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct12.3K shares at avg. $6.57$81K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct11.3K shares at avg. $42.74$482K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct11.3K shares at avg. $15.96$180K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct34K shares at avg. $42.74$1.5M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 18, 2026 |  RNA Atrium Therapeutics, Inc. | Tax Payment(F) | 21,459 | $8.95 | $192,058 | Direct |
| Apr 20, 2026 | RNA Atrium Therapeutics, Inc. | Award(A) | 30,000 | - | $0 | Direct |
| Feb 27, 2026 |  RNAM Avidity Biosciences, Inc. | Disposition(D) | 115,857 | - | $0 | Direct |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 2,878 | $72.45 | $208,511 | Direct |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 2,017 | $72.45 | $146,132 | Direct |
| Jan 7, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 2,373 | $72.23 | $171,402 | Direct |
| Oct 22, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 2,209 | $10.16 | $22,443 | Direct |
| Oct 22, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 2,209 | $47.54 | $105,015 | Direct |
| Sep 22, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 2,208 | $40.58 | $89,601 | Direct |
| Sep 22, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 2,208 | $10.16 | $22,433 | Direct |
| Sep 15, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 1,542 | $45.41 | $70,022 | Direct |
| Sep 15, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 1,542 | $6.57 | $10,131 | Direct |
| Aug 22, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 2,208 | $10.16 | $22,433 | Direct |
| Aug 22, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 2,208 | $46.40 | $102,462 | Direct |
| Aug 13, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 1,542 | $46.66 | $71,950 | Direct |
| Aug 13, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 1,542 | $6.57 | $10,131 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 17,667 | $42.74 | $755,040 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 17,667 | $10.16 | $179,497 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 6,167 | $42.74 | $263,561 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 6,167 | $22.47 | $138,572 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 12,334 | $42.74 | $527,122 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 12,334 | $6.57 | $81,034 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 11,283 | $42.74 | $482,205 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 11,283 | $15.96 | $180,077 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 33,983 | $42.74 | $1,452,342 | Direct |
1-25 of 29 transactions
About Hughes Steven George
Hughes Steven George (SEC CIK 0001747528) files insider reports with the SEC as Chief Medical Officer of Atrium Therapeutics, Inc. (RNA) and Chief Medical Officer of Avidity Biosciences, Inc. (RNAM).
Signal8 holds 16 ownership filings by Hughes Steven George (2 Form 3, 14 Form 4), filed between Jan 8, 2025 and Sep 22, 2026. Those filings report 29 transactions, from Jan 6, 2025 to Sep 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hughes Steven George's filings is in SAN DIEGO, CA.
Recent filings by Hughes Steven George
- Sep 18, 2026: Tax withholding of RNA shares (Form 4, code F).
- Apr 20, 2026: Grant or award of RNA shares (Form 4, code A).
- Feb 27, 2026: Disposition to issuer transaction of RNAM shares (Form 4, code D).
- Jan 21, 2026: Open-market sales of RNA shares (2 lines, Form 4, code S).
- Jan 7, 2026: Open-market sale of RNA shares (Form 4, code S).
Other insiders filing for Atrium Therapeutics, Inc. (RNA)
- Younis Husam, Chief Scientific Officer
- Flanagan W. Michael, Director
- Boyce Sarah, Director
- Kenney Stephanie
- Gallagher Kathleen P.
- Winslow Brendan R., Chief Financial Officer